About US
Contact us
-
GSK, Takeda say nay to in-house diagnostics unitsGlaxoSmithKline ($GSK) and Takeda Pharmaceutical are choosing the partnerships side of the divide when it comes to developing diagnostics to team up with their drugs. Both companies have said they2012/2/13
-
Merck says Victrelis can interfere with HIV medsMerck ($MRK)has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck s2012/2/13
-
Novartis CEO calls external focus key to fast-changing pharmaThe idea of facing generic competition for a $5 billion blockbuster like Diovan would daunt almost any CEO. But Joe Jimenez (photo) says his experience hawking baby food and ketchup at Heinz m2012/2/10
-
Judge: No 1st Amendment shield for Astellas' Prograf petitionJapan's Astellas Pharma has to fight antitrust claims related to its transplant drug Prograf. The drugmaker failed to persuade a U.S. judge to dismiss consumer allegations it petitioned the FDA2012/2/10
-
Sanofi CEO: Look out below, profits are fallingIt wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3 billion). The headl2012/2/9
-
GSK moves European cash to U.K. nightly 'just in case'GlaxoSmithKline ($GSK) executives like to sleep well at night, not wake up worrying about a banking crisis. So, the company transfers millions of euros every day into U.K. bank accounts to keep cash2012/2/9
-
Sanofi, BMS collect their $444M in Plavix damagesApotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ($SNY) and Bristol-Myers Squibb ($BMY), as repayment for its premature launch of generic Plavix bac2012/2/9
-
FDA issues safety alert about PPIs and C. diffThe FDA announced that proton-pump inhibitors used to treat heartburn and acid reflux can increase the risk of diarrhea associated with Clostridium difficile, and said it was working with drugmake2012/2/9
-
Reuters: Nestle leads pack of bidders for Pfizer nutrition unitNestle is the front-runner for Pfizer's nutrition business, Reuters' sources say. The Swiss company is vying with France's Danone for the Pfizer ($PFE) unit, which the drugmaker marked for sale or s2012/2/8
-
Hang on just a bit longer for sales growth, GSK chief saysThings are looking up for GlaxoSmithKline ($GSK)--just not quite yet. We've heard CEO Andrew Witty (photo)talk about "underlying sales growth" for several quarters now, and this earnings announcement2012/2/8